Ocugen (OCGN) said Wednesday that the US Food and Drug Administration had lifted the clinical hold on its investigational new drug application for the phase 1 trial of its experimental drug, OCU200, a recombinant fusion protein used to treat diabetic macular edema.
The company said it also plans to explore additional uses for OCU200, including potentially treating diabetic retinopathy and wet age-related macular degeneration.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。